Skip to main content
OpenTrials
Completed

NCT Number: NCT00250341

Non-invasive Measures of Distal Lung Disease in Asthmatics

This is a Phase 4, single center study conducted in mild-to moderate asthmatics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

UCLA

Los Angeles, California, 90095, United States

About this study

The study consists of 3 phases. There are 7 study visits.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-65 years old
  • Currently using SABA prn or a low-to-moderate persistent asthma

Exclusion criteria

  • Tobacco use within 1 year or >= 5 pack years

Treatment and study plan

QVAR

Drug

480 mcg

Other names: beclomethasone dipropionate HFA

Advair

Drug

250/50 mcg

Other names: Advair Diskus

Servent Diskus

Drug

50 mcg

Primary outcomes

  1. High resolution Cat Scans

Sponsors and collaborators

Lead sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Industry

Registry information

Official study title

Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Therapy Directed at the Proximal vs. Distal Lung

Important dates

Study start
2005
Primary completion
2007
Study completion
2007
First posted
Nov 8, 2005
Registry last updated
Dec 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.